The Risk of Developing Non-Alcoholic Fatty Liver Disease in Adult Patients with Subclinical Hypothyroidism Compared to Euthyroid: An Evidence-based Case Report by Notariza, Kemas Rakhmat & Wisnu, Wismandari
SPECIAL  ARTICLE
179Acta Med Indones - Indones J Intern Med • Vol 51 • Number 2 • April 2019
The Risk of Developing Non-Alcoholic Fatty Liver Disease in 
Adult Patients with Subclinical Hypothyroidism Compared 
to Euthyroid: An Evidence-based Case Report
Kemas R. Notariza1, Wismandari Wisnu2
1 Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
2 Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, 
Jakarta, Indonesia.
Corresponding Author:
Wismandari Wisnu, MD. Division of Metabolic and Endocrinology, Department of Internal Medicine, Faculty of 
Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital. Jl. Diponegoro no. 71, Jakarta 10430, Indonesia. 
email: wisma_slamet@yahoo.com; kemasnotariza@yahoo.com.
ABSTRAK
Latar belakang: hipotiroidisme merupakan penyakit penyerta yang sering ditemukan pada pasien dengan 
penyakit perlemakan hati non-alkoholik (non-alcoholic fatty liver disease [NAFLD]). Penelitian-penelitian 
terdahulu mengenai hubungan antara hipotiroidisme subklinis dan NAFLD memperlihatkan hasil yang 
bertentangan, mulai dari hubungan kuat hingga asosiasi yang tidak signifikan. Laporan kasus ini bertujuan 
untuk menginvestigasi risiko berkembangnya NAFLD pada pasien hipotiroidisme subklinis. Metode: penelusuran 
literatur menggunakan basis data ScienceDirect, PubMed, ProQuest, dan Scopus. Penapisan judul dan abstrak 
dengan kriteria inklusi dan eksklusi menghasilkan 4 artikel (1 telaah sistematis, 1 kohort prospektif, 1 kohort 
retrospektif, dan 1 studi kasus-kontrol) yang sesuai untuk menjawab pertanyaan klinis. Telaah kritis dilakukan 
dengan menggunakan lembar kerja dari Centre for Evidence-Based Medicine, University of Oxford. Hasil: telaah 
sistematis dianggap tidak valid karena memiliki penelusuran yang kurang komprehensif terhadap studi-studi 
terkait, seleksi artikel yang kurang tepat untuk menyimpulkan hubungan kausal antarpenyakit, dan heterogenitas 
statistik. Kohort retrospektif dinilai tidak penting karena memiliki risiko relatif 0,85 (interval kepercayaan [IK] 
95%, 0,72—1,00) yang batas atas IK-nya meliputi 1,00. Dua artikel lainnya valid serta memiliki risiko relatif 
dan rasio odds yang penting (1,27 [IK 95%, 1,09—1,47], 3,41 [IK 95%, 1,16—9,98]; berturut-turut). Number 
needed to harm (5—17) mengindikasikan bahaya yang bermakna secara klinis dari pajanan hipotiroidisme 
subklinis karena hanya sedikit pasien dengan hipotiroidisme subklinis yang dibutuhkan untuk memperoleh 
tambahan satu insidens NAFLD. Kedua artikel tersebut juga memiliki kemamputerapan yang baik untuk kasus 
ini. Kesimpulan: pasien dengan hipotiroid subklinis, dibandingkan dengan pasien eutiroid, berisiko lebih tinggi 
untuk mengalami NAFLD.
Kata kunci: eutiroid, hipotiroidisme subklinis, penyakit perlemakan hati non-alkoholik.
ABSTRACT
Background: hypothyroidism is a common concomitant disease of non-alcoholic fatty liver disease (NAFLD). 
Previous studies regarding the relationship between subclinical hypothyroidism and NAFLD showed conflicting 
results, ranging from a strong association to not significant one. This case report aimed to investigate the risk of 
developing NAFLD in subclinical hypothyroidism patients. Methods: literature searching used ScienceDirect, 
PubMed, ProQuest, and Scopus. Filtering process of titles and abstracts by using inclusion and exclusion criteria 
yielded 4 eligible articles (1 systematic review, 1 prospective cohort, 1 retrospective cohort, and 1 case-control 
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study) for answering the clinical question. Critical appraisal was conducted by using worksheets from Centre 
for Evidence-Based Medicine, University of Oxford. Results: the systematic review was considered invalid due 
to its less comprehensive search for relevant studies, inappropriate article selection to find a causal relationship 
between diseases, and statistical heterogeneity. The retrospective cohort was decided unimportant because it 
possessed a relative risk of 0.85 (95% confidence interval [CI], 0.72--1.00) which the upper limit of its CI included 
1.00. The rest were valid and had important risk relative and odds ratio (1.27 [95% CI, 1.09--1.47], 3.41 [95% 
CI, 1.16--9.98]; respectively). The number needed to harm (5—17) indicated the clinically meaningful harm 
of the exposure since only a few patients with subclinical hypothyroidism is needed to obtain one additional 
NAFLD incidence. Those two articles were also suitable to be applied in our case. Conclusion: patients with 
subclinical hypothyroidism, compared to euthyroid patients, are at higher risk of developing NAFLD.
Keywords: euthyroid, non-alcoholic fatty liver disease, subclinical hypothyroidism.
INTRODUCTION
Subclinical hypothyroidism is a condition 
characterized by an elevated levels of thyroid 
stimulating hormone (TSH) with a normal free 
thyroxine (FT4) levels.1 This is a quite common 
condition found across various populations. 
The Colorado Thyroid Disease Prevalence 
Study found that the prevalence of subclinical 
hypothyroidism in United States is 9.0%, 
whereas the prevalence in India is 8.9% 
according to the South Indian Population 
Study.2,3 Its prevalence in Indonesia is still 
undetermined.4 The risk factors associated with 
subclinical hypothyroidism comprises female 
sex, advancing age, and suboptimal iodine 
status.2 In the other hand, non-alcoholic fatty 
liver disease (NAFLD) has been recognized 
as the most common cause of abnormal liver 
function worldwide. The global prevalence 
of NAFLD is 24%, with the highest rates are 
reported from South America, the Middle East, 
and Asia.5
NAFLD is a wide spectrum of liver 
clinicopathologic conditions, varying from a 
benign condition called pure fatty steatosis (fatty 
infiltration in >5% of hepatocytes) to a heavier 
condition called non-alcoholic steatohepatitis 
(NASH). NASH may progress to cirrhosis, 
liver failure, and hepatocellular carcinoma. 
The key characteristic of NAFLD is excessive 
fat accumulation in the liver parenchyma of 
patients without any history of alcohol abuse 
(<20 g per day in men and <10 g in women).6 
NAFLD is strongly associated with metabolic 
syndrome, which is also linked to subclinical 
hypothyroidism.7,8 Considering the important 
role of thyroid hormone in lipid metabolism, 
hypothyroidism may cause hyperlipidemia 
which plays a crucial role in the pathogenesis 
of NAFLD.9
The prevalence of hypothyroidism was 
higher among NAFLD patients compared to 
controls (21% vs 9.5%, p <0.01), indicating 
that hypothyroidism is a common concomitant 
disease of NAFLD and may have an association 
with the NAFLD development.10 A recent 
study showed that the decreased levels of FT4, 
as happening in overt hypothyroidism, can 
escalate the risk of NAFLD.11 However, previous 
studies regarding the relationship between 
subclinical hypothyroidism and NAFLD yielded 
conflicting results, varying from a strong 
association to no association.9,12,13 Therefore, 
the causal relationship between them remains 
in dispute up to now. In this evidence-based 
case report, we aimed to determine the risk of 
developing NAFLD in patients with subclinical 
hypothyroidism.
CASE ILLUSTRATION
A 57-year-old female presented to a clinic, 
complaining of a progressive weight gain of 
around 15 kilograms over the past 6 months. 
She also reported cold intolerance and fatigue. 
Neither history of diabetes or of hypertension 
was identified. Family history was significant 
for an unclear thyroid disease in her mother, 
who passed away due to a liver disease. Vital 
signs were within normal limits. The body mass 
index was 26.3 kg/m2. Thyroid enlargement was 
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not present. Other physical examination was 
unremarkable. 
Complete blood count and serum electrolytes 
were normal. Serum cholesterol was 270 mg/dL 
(N < 200). The TSH levels was 9.1 mIU/mL (N 
= 0.4-4.3), and the FT4 concentration was 1.17 
ng/dL (N = 0.8-1.7). She was suspected suffering 
subclinical hypothyroidism and was planned to 
repeat the laboratory tests in the following 3 
months before the diagnosis could be established. 
The patient, as well as the medical doctor, would 
like to know whether subclinical hypothyroidism 
could raise the risk of developing NAFLD.
CLINICAL QUESTION
We formulated a clinical question based on 
the Patient, Indicator, Comparison, and Outcome 
(PICO) format as follows:
• Patient (P): Adults (aged 18 years or older);
• Indicator (I): Subclinical hypothyroidism;
• Comparison (C): Euthyroid;
• Outcome: Development of NAFLD.
Here is the clinical question: Are the adult 
patients with subclinical hypothyroidism, 
compared to euthyroid patients, at higher risk 
of developing non-alcoholic fatty liver disease?
Table 1. Searching strategy
Search 
Engine Terms
Articles 
Found
Articles 
Used
Science 
Direct
(“subclinical hypothyroid“ OR “subclinical hypothyroidism“ OR “mild thyroid failure”) AND 
(euthyroid OR normal thyroixine) AND (“NAFLD” OR “non alcoholic fatty liver disease“ 
OR “nonalcoholic fatty liver disease“ OR “nonalcoholic steatohepatitis“)
2 0
PubMed
(((((((((((subclinical hypothyroid[Title/Abstract]) OR subclinical hypothyroidism[Title/
Abstract]) OR subclinical thyroid stimulating hormone deficiency[Title/Abstract]) OR 
subclinical thyroid stimulating hormone deficiencies[Title/Abstract]) OR subclinical 
thyroid-stimulating hormone deficiency[Title/Abstract]) OR subclinical thyroid-
stimulating hormone deficiencies[Title/Abstract]) OR mild thyroid failure[Title/Abstract]) 
OR subclinical tsh deficiency[Title/Abstract]) OR subclinical tsh deficiencies[Title/
Abstract])) AND (((((((euthyroid[Title/Abstract]) OR normothyroid[Title/Abstract]) 
OR normal thyroid[Title/Abstract]) OR normal thyroxine[Title/Abstract]) OR normal 
free thyroxine[Title/Abstract]) OR normal free t4[Title/Abstract]) OR normal ft4[Title/
Abstract])) AND ((((((((((((((((NAFLD[Title/Abstract]) OR non alcoholic fatty liver 
disease[Title/Abstract]) OR non-alcoholic fatty liver disease[Title/Abstract]) OR 
nonalcoholic fatty liver disease[Title/Abstract]) OR non alcoholic fatty liver[Title/
Abstract]) OR non-alcoholic fatty liver[Title/Abstract]) OR nonalcoholic fatty liver[Title/
Abstract]) OR non alcoholic fatty livers[Title/Abstract]) OR non-alcoholic fatty 
livers[Title/Abstract]) OR nonalcoholic fatty livers[Title/Abstract]) OR nonalcoholic 
steatohepatitis[Title/Abstract]) OR non-alcoholic steatohepatitis[Title/Abstract]) OR 
nonalcoholic steatohepatitis[Title/Abstract]) OR nonalcoholic steatohepatitides[Title/
Abstract]) OR non-alcoholic steatohepatitides[Title/Abstract]) OR non alcoholic 
steatohepatitides[Title/Abstract])
7 3
ProQuest
ab(subclinical hypothyroid OR subclinical hypothyroidism OR subclinical thyroid 
stimulating hormone deficiency OR subclinical thyroid stimulating hormone deficiencies 
OR subclinical thyroid-stimulating hormone deficiency OR subclinical thyroid-stimulating 
hormone deficiencies OR mild thyroid failure OR subclinical tsh deficiency OR 
subclinical tsh deficiencies) AND ab(euthyroid OR porphyroid OR normal thyroid OR 
normal thyroxine OR normal thyroxine OR normal free thyroxine OR normal free t4 
OR normal ft4) AND ab(nafld OR non alcoholic fatty liver disease OR non-alcoholic 
fatty liver disease OR nonalcoholic fatty liver disease OR non alcoholic fatty liver OR 
non-alcoholic fatty liver OR nonalcoholic fatty liver OR non alcoholic fatty livers OR 
non-alcoholic fatty livers OR nonalcoholic fatty livers OR non alcoholic steatohepatitis 
OR nonalcoholic steatohepatitis OR non-alcoholic steatohepatitis OR non alcoholic 
steatohepatitis OR non-alcoholic steatohepatitis OR nonalcoholic steatohepatitis OR 
non alcoholic steatohepatitides OR nonalcoholic steatohepatides OR non-alcoholic 
steatohepatides)
15 1
Scopus
( TITLE-ABS-KEY ( "subclinical hypothyroid"  OR  "subclinical hypothyroidism"  OR 
"subclinical thyroid stimulating hormone deficiency"  OR  "subclinical thyroid-stimulating 
hormone"  OR  "mild thyroid failure"  OR  "subclinical tsh deficiency" )  AND  TITLE-
ABS-KEY ( euthyroid  OR  normothyroid  OR  "normal thyroid"  OR  "normal thyroxine" 
OR  "normal free thyroxine"  OR  "normal free t4"  OR  "normal ft4" )  AND  TITLE-ABS-
KEY ( nafld  OR  "non alcoholic fatty liver disease"  OR  "non alcoholic fatty liver"  OR 
"non alcoholic steatohepatitis"  OR  "non alcoholic hepatitides" ) )
6 0
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METHODS
The article searching was performed in 
ScienceDirect, PubMed, ProQuest, and Scopus 
on July 14, 2018. The keywords of “subclinical 
hypothyroidism”, “euthyroid”, and “non-
alcoholic fatty liver disease” along with their 
synonyms and related terms were used during 
the search. We omitted the keyword of “adult” 
because of the lack of results, yet it did not 
necessarily affect the finding and study analysis. 
The terminology applied in each of the databases 
is listed in Table 1.
Literature searching found several articles. 
The selection was conducted based on inclusion 
criteria, consisting of: (1) human; (2) comparative 
study; (3) meta-analysis/systematic reviews; 
(4) journal/research articles; (5) observational 
study; and (6) English. The yielded articles 
would be excluded if they were irrelevant to 
the clinical question, or their study design was 
cross-sectional.
Selection
There were 2 articles from ScienceDirect, 
7 from PubMed, 15 from ProQuest, and 6 
from Scopus yielded in literature searching. 
Limitation by using the inclusion criteria was 
then applied and there were 2 articles obtained 
from ScienceDirect, 4 from PubMed, 7 from 
ProQuest, and 6 from Scopus. After screening 
the title and abstract of each article, 6 articles 
with no double were found relevant to the clinical 
question. The full-text of those articles were 
available, and a thorough reading over them 
concluded that there were 4 useful articles to be 
reviewed for answering the clinical question. A 
flowchart summarizing the searching strategy 
and its results is shown in Figure 1.
Critical Appraisal
Four articles attained in literature searching 
were comprised of 1 systematic review, 1 
prospective cohort, 1 retrospective cohort, and 
1 case-control study. After the selection, critical 
Figure 1. Flowchart of searching strategy.
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appraisal was done by using worksheets from 
Center of Evidence-Based Medicine (CEBM), 
University of Oxford for etiologic studies or for 
systematic reviews.14
RESULTS
He et al.15 conducted a systematic review 
of observational studies, aiming to evaluate 
the relationship between hypothyroidism 
and NAFLD. They searched PubMed, China 
Dissertation Database, and EMBASE. Thirteen 
studies were eventually included for the final 
study analysis. Those were consisted of 2 cohort, 
4 case-control, and 7 cross-sectional studies. 
Subgroup analysis showed that the pooled odds 
ratio (OR) of NAFLD in patients with subclinical 
hypothyroidism is 1.40 (95% confidence interval 
[CI], 1.10-1.77). They drew a conclusion that 
subclinical hypothyroidism is independently 
associated with NAFLD.
A large population-based, prospective cohort 
study by Bano et al.16 aimed to investigate 
the association between variations in thyroid 
function and NAFLD spectrum. This study was 
conducted at Ommoord district in Rotterdam, the 
Netherlands, and consisted of 3 periods of cohort 
(1990-1993, 2000, and 2006). A total of 14,926 
subjects were enrolled and were comprised of 
7,893 participants aged 55 years and over in 
the first cohort, 3,011 participants with same 
age limitation in the second cohort, and 3,932 
participants aged 45 years or older in the last 
cohort. There were 9,419 participants eligible 
for study analysis. In this study, the relative risk 
(RR) of subclinical hypothyroidism, compared 
to euthyroid, in developing NAFLD is 1.27 
(95% CI, 1.09–1.47) and the number needed to 
harm (NNH) is 17. They concluded that lower 
thyroid function is associated with an increased 
risk of NAFLD.
A 4-year retrospective cohort study by Lee 
et al.17 aimed to compare the risk of developing 
NAFLD among three groups with different 
thyroid hormonal status (overt hypothyroidism, 
subclinical hypothyroidism, and control). 
They included 18,544 apparently healthy 
subjects without NAFLD aged 20-65 years who 
underwent annual health check-ups between 
2008-2012 at the Health Promotion Center of 
Kangbuk Samsung Health Hospital, Korea. In 
this study, the RR of developing NAFLD in 
subclinical hypothyroid subjects is 0.85 (95% CI 
0.72-1.00) and the NNH is -50. They suggested 
that both subclinical hypothyroidism and overt 
hypothyroidism are not related to an increased 
incidence of NAFLD.
Parikh et al.18 conducted a case-control 
study, aiming to assess the prevalence of 
hypothyroidism in patients with NAFLD 
and to assess potential factors (dyslipidemia, 
obesity, diabetes) that could be linked with 
hypothyroidism. They entailed 800 adult patients 
in the Gastroenterology outpatient clinic of the 
Lokmanya Tilak Municipal Medical College and 
General Hospital, Mumbai, India. This study 
found that the prevalence of hypothyroidism in 
NAFLD is 16.8%. In this study, OR of NAFLD in 
subclinical hypothyroidism patients is 3.41 (95% 
CI 1.16-9.98) and the NNH is 5. They confirmed 
a significant clinical relationship between these 
two diseases.
The characteristics and relevant outcome of 
each yielded study are summarized in Table 2.
The critical appraisal result of the systematic 
review is provided in Table 3. Critical appraisal 
results of the cohort and case-control studies is 
reported in Table 4.
DISCUSSION
We appraised the validity of the systematic 
review by He et al.15 In their title and abstract, 
they stated clearly the main research question 
being addressed, that is the relationship between 
hypothyroidism and NAFLD. The authors 
unfortunately carried out literature searching only 
in major bibliographic databases without any 
mentioned attempt to find related hand-searching 
journals, theses, conference proceedings, nor to 
contact experts for inquiring about unpublished 
articles. That is why we assessed that this review 
had less comprehensive search. In scrutinizing 
the inclusion of studies, we found that the 
authors kept including cross-sectional studies 
that makes this review lack of reliability to 
determine the causal relationship between 
subclinical hypothyroidism and NAFLD. Hence, 
we considered that this eligibility criteria makes 
us unable to rely on the results of this systematic 
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review to answer our clinical question. It is 
worth notice that the authors reported how 
they assess the quality of each study, that is by 
using Newcastle Ottawa Scale. This systematic 
review still had statistical heterogeneity and the 
study design was thought as the possible source. 
Overall, we decided that this systematic review 
is not valid to answer our clinical question. 
Therefore, we did not continue to further process 
of critical appraisal of this systematic review.
In the validity analysis of the prospective 
cohort study by Bano et al.16, we found that the 
exposed groups and the controls were clearly 
defined. Both groups were similar because 
the authors had done adjustment for age, sex, 
follow-up time, use of hypolipidemic drugs, and 
cardiovascular risk factors. Thyroid function 
measurement and abdominal ultrasound for 
NAFLD diagnosis were performed in the same 
way in both groups. A single trained technician 
performed the abdominal ultrasonography and 
the images were reevaluated by an experienced 
hepatologist, though it was not mentioned 
whether the assessors were blinded to the thyroid 
status of participants. The median follow-up time 
was 10.04 (5.70-10.99) years and it is sufficiently 
long as Xu et al.19 had found that 19.26% of 
subclinical hypothyroid subjects developed 
NAFLD during a median follow-up of 4.92 years. 
To make sure that the subclinical hypothyroidism 
preceded the onset of NAFLD, the authors had 
performed fatty liver index measurements at the 
beginning of study. The concept of “dechallange-
rechallenge” is not applicable in this study. We 
found that the association in this study consistent 
with the study result of Kim et al.20 which showed 
Table 2. Characteristics and relevant outcome of the Yielded studies
Article Country Study Design
Participants 
(mean age 
[years old]; 
female %)
Definition of 
Subclinical 
Hypothyroidism
Diagnosis 
of NAFLD
Relevant 
Outcome
He et al.15 China Systematic 
review
13 studies 
included: 2 
cohort, 4 case-
control, and 7 
cross-sectional 
studies
Varying reference 
ranges among 
studies
11 studies by 
abdominal 
ultrasound, 
2 studies by 
enzymatic 
procedures, 
1 study by 
histological 
examination
Patients with 
subclinical 
hypothyroidism are 
at a higher risk for 
the development 
of NAFLD 
than euthyroid 
individuals (OR 
1.40; 95% CI, 
1.10-1.77)
Bano et al.16 Netherlands Prospective 
cohort (median 
follow up time: 
10.04 [5.70-
10.88] years)
9,419 subjects 
(64.7; 56.5)
Serum TSH > 4.0 
mIU/L and FT4 
between 0.85-
1.95 ng/dL
Abdominal 
ultrasound 
Compared 
with euthyroid, 
subclinical 
hypothyroidism is 
associated with 
a 1.27-fold (95% 
CI, 1.087–1.469) 
higher risk of 
having NAFLD.
Lee et al.17 Korea Retrospective 
cohort (follow 
up time: 4 
years)
18,544 subjects 
(37.8 ± 5.7; 50)
TSH > 4.2 mIU/L 
and FT4 between 
0.97-1.68 ng/dL
Abdominal 
ultrasound
Subclinical 
hypothyroidism is 
not a risk factor for 
developing NAFLD 
(hazard ratio [HR] 
0.847; 95% CI, 
0.715-1.003).
Parikh et 
al.18
India Case-control 500 NAFLD 
patients (44.3 ± 
3.2; 64.6), 300 
controls (41.6 ± 
3.89; 66)
TSH > 5.5 IU/
mL but < 10 IU/
mL, and FT4 
levels within the 
reference range
Abdominal 
ultrasound
The odds ratio 
(OR) of NAFLD 
in subclinical 
hypothyroidism 
patients is 3.406 
(95% CI, 1.162-
9.981)
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Table 3. Critical appraisal of systematic review
Article Year Study Design
Level of 
Evidence
Validity
Statement 
of the Main 
Question
Comprehensive 
Search
Appropriate 
Selection
Quality 
Assessment 
of Each Study
Homogenity
He et 
al.15 2017
Systematic 
review of 
cohort, 
case-
control, and 
cross-
sectional 
studies
3a + - - + -
Table 4. Critical appraisal of cohort and case-control studies
Bano et al.16 Lee et al.17 Parikh et al.18
Year
Study Design 2016 2015 2015
Level of Evidence Prospective cohort Retrospective cohort Case-control
Validity 2b 2b 3b
 - Similarity between Two 
Groups
 - Same Way of 
Measurement Yes Yes Yes
 - Adequate Follow Up Yes Yes Yes
 - Exposure Preceding 
Outcome Yes Yes Yes
 - Dose-Response 
Gradient Yes Yes No
 - Dechallenge - 
Rechallenge Yes Yes Yes
 - Consistent Association Not applicable Not applicable Not applicable.
 - Biological Sense Yes Yes Yes
Importance Yes Yes Yes
 - RR (for Cohort Study)/ 
OR (for Case-Control 
Study) (95% CI)
1.27 (1.09-1.47) 0.85 (0.72-1.00) 3.41 (1.16-9.98)
 - EER 0.28 0.11 0.85
 - CER 0.22 0.13 0.62
 - RRI 0.27 - 0.15 0.37
 - ARI 0.06 - 0.02 0.23
 - NNH 17 - 50 5
Applicability
 - Applicable to Our 
Practice Yes - Yes
 - Potential Benefit and 
Harm from Agent Not relevant - Not relevant
 - Patient's Preferences 
and Concerns Yes - Yes
 - Availability of Alternative 
Treatments Not relevant - Not relevant
ARI: absolute risk-increase; CER: control event rate; CI: confidence interval; EER: exposed event rate; NNH: number 
needed to harm; OR: odds ratio; RR: relative risk; RRI: relative risk-increase
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the relationship between these diseases. The 
results of this study was also supported by the 
evidence of the physiological role of thyroid 
hormone in lipid metabolism.9 Hence, we came 
to a decision that this evidence is valid to answer 
our clinical question.
We found in the cohort study by Bano et al.16 
that the NNH is 17, meaning that we need to 
have 17 patients with subclinical hypothyroidism 
to find 1 incidence of NAFLD. The RR in 
this study is 1.27, with 95% CI of 1.09-1.47. 
This confidence interval is narrow and stays 
within a clinically important increased risk. We 
considered that the valid results of this study are 
important.
Most of the patients enrolled in the cohort 
study by Bano et al.16 were aged 55 years or older, 
and more than a half of them were female. So, 
our patient is not so different from those included 
in this study. The focus of interest in this study 
also resembles the concern of our patient. At 
last, we decided that this valid and important 
evidence about the risk of developing NAFLD 
in subclinical hypothyroidism individuals can be 
applied to our patient.
Appraisal of validity of the retrospective 
cohort study by Lee et al.17 revealed that the 
exposed groups and the controls were clearly 
defined. The similarity of both groups was 
reassured by the adjustment for sex, age, body 
mass index, triglyceride and HDL levels. 
Assessment of initial levels of serum FT4, 
TSH, other biochemical indicators, as well as 
abdominal ultrasonography were performed in 
all subjects. The experienced radiologists were 
blinded to the clinical status of the subjects 
when they performed the ultrasounds. The 
follow-up time was 4 years and it is sufficiently 
long according to the finding in Xu et al.19 
The authors had excluded patients with initial 
fatty liver disease and only included healthy 
subjects without NAFLD, so we can have higher 
confidence that the subclinical hypothyroidism 
really preceded the onset NAFLD found in a later 
time. The concept of “dechallange-rechallenge” 
is not applicable in this study either. The negative 
association of subclinical hypothyroidism and 
NAFLD in this research is similar to the study 
by Mazo et al.9 As a support for biological 
plausibility for this finding, Eshragian et 
al.13 suggested that alterations in TSH levels 
in NAFLD patients is due to sick euthyroid 
syndrome, instead of subclinical hypothyroidism. 
Therefore, we reached a decision that the results 
of this study are valid.
The NNH in the cohort study by Lee et al.17 
is -50. This negative NNH indicates that the 
subclinical hypothyroid patients are less likely 
to develop NAFL than the euthyroid individuals. 
The RR in this study is 0.85, suggesting that 
subclinical hypothyroidism is the protective 
factor of NAFLD. The possible cause of this 
finding is that the participants included in this 
study were too young to develop NAFLD as 
the mean age of euthyroid group was 34.6 (SD 
4.9) years old, while the mean age of subclinical 
hypothyroid group was 34.2 (SD 5.1) years old. It 
has been reported in another study that one of the 
risk factors of developing NAFLD is older age.1
However, the precision of these results is 
questionable since the 95% CI is 0.72-1.00. 
Because the upper limit of CI includes 1.00, there 
is a possibility that no significant relationship 
exists between those diseases in the actual 
population. Considering that the credibility of 
this study is not so fine, we decided that this 
evidence is valid, but not important. Thus, we 
did not continue appraising the applicability of 
this cohort study.
In the case-control study by Parikh et al.18, 
validity appraisal found that the case group and 
the control group were well defined. Adjustment 
had been done for age, gender, alcohol use, and 
serum triglyceride levels to make both groups 
identical. All patients were evaluated in the 
same way for history, physical examination, 
thyroid profile, other laboratory tests, and 
abdominal ultrasound. It was not stated whether 
the assessors were blinded to the outcome and 
study hypothesis. No long follow-up period is 
needed because the outcome could be identified 
since the beginning of the case-control study. 
However, the study design makes it difficult 
to determine the temporal sequence between 
subclinical hypothyroidism as the exposure 
and NAFLD as outcome. The concept of 
“dechallange-rechallenge” is not applicable 
in this study. The association of subclinical 
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hypothyroidism and NAFLD in this study 
resembles the study result of Kim et al.20 that 
showed a significant relationship between these 
diseases. The evidence of the fundamental role of 
thyroid hormone in lipid metabolism supported 
the results of this study.9 Therefore, we reached 
a decision that this evidence is valid.
In the importance analysis of the case-
control study by Parikh et al.18, we found the 
NNH is 5, indicating that we need to have 5 
patients with subclinical hypothyroidism to find 
1 new incidence of NAFLD. The OR in this 
study is 3.41 (95% CI, 1.16-9.98). Although the 
confidence interval is not narrow, it stays within 
a clinically important increased risk. Thus, we 
decided that the valid results of this study are 
important.
The patients enrolled in the case-control 
study by Parikh et al.18 were mostly women. 
The mean BMI of the NAFLD group was 29.15 
(SD 0.56) kg/m2, while the mean BMI of the 
control group was 27.14 (SD 0.54) kg/m2. These 
characteristics resembles our patient’s, so our 
patient is not so different from the subjects in 
this study. The focus of interest in this study also 
suites our patient’s concern. Finally, we came to 
a decision that this valid and important evidence 
about the risk of NAFLD development in adults 
with subclinical hypothyroidism can be applied 
to our patient.
Overall, we had 2 valid, important, and 
applicable articles to answer our clinical 
question. Both articles highlighted the higher 
risk of developing NAFLD in patients with 
subclinical hypothyroidism. The foundation for 
our findings has been laid by several studies 
providing some possible explanations about the 
molecular mechanism underlying the causal 
relationship between subclinical hypothyroidism 
and NAFLD. Firstly, subclinical hypothyroidism 
is associated with insulin resistance.21 At the 
same time, it has also been reported that insulin 
resistance represents the pathophysiological 
hallmark of NAFLD.22
Secondly, TSH can promote the hepatic 
expression of 3-hydroxy-3-methyl-glutaryl 
coenzyme A reductase (HMGCR), a rate-
limiting enzyme in cholesterol synthesis. 
The mechanism of action is that TSH bind 
to its receptors in hepatocyte membranes, 
stimulating the signaling system of cyclic 
adenosine monophosphate/protein kinase A/
cyclic adenosine monophosphate-responsive 
element binding protein (cAMP/PKA/CREB). 
This may be a potential mechanism for 
hypercholesterolemia involving direct action of 
TSH on the liver.23
Ultimately, patients with subclinical 
hypothyroidism may suffer  secondary 
hypercholesterolemia which is associated with 
oxidative stress. Santi et al.24 reported that 
subclinical hypothyroid patients, compared with 
the control group, are under increased oxidative 
stress which is characterized by lower activity 
of arylesterase, an enzyme with protective role 
against peroxidation of low-density lipoprotein 
(LDL) and other lipoproteins. They also 
found a significant correlation between lipids 
(triglyceride and LDL-C) and TSH.
CONCLUSION
Patients with subclinical hypothyroidism, 
compared to euthyroid patients, are at higher risk 
of developing NAFLD. Therefore, we can give 
an evidence-based answer to our patients about 
her greater risk of developing this liver disease 
if the diagnosis of subclinical hypothyroidism 
has been established. The screening of, as well 
as the preventive management (e.g. prescribing a 
reduced calorie, low-fat diet and regular exercises 
with the goal of controlling body weight) of 
NAFLD in subclinical hypothyroidism patients 
may be helpful to anticipate the poor outcome.
STATEMENT OF PRIOR PRESENTATION
This case report was presented in the form 
of scientific poster at the 16th Asia-Oceania 
Congress of Endocrinology (AOCE), September 
27-30, 2018 in Yogyakarta, Indonesia.
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